Home › Funds › Tower Research Capital LLC (TRC) › GSK
Tower Research Capital LLC (TRC) position in GSK
GSK PLC · Health Care
Tower Research Capital LLC (TRC) reported holding 463,125 shares of GSK (GSK PLC) in its Q2 2026 13F filing — a position valued at US$24.3M, representing 0.59% of its reported portfolio and ranking #29 among its reported holdings. Tower Research Capital LLC (TRC) has disclosed GSK holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Tower Research Capital LLC (TRC)'s GSK position evolved
Tower Research Capital LLC (TRC) first disclosed a stake in GSK in Q3 2023 at 717 shares (US$26K). The position peaked in Q2 2026 at 463,125 shares, worth US$24.3M. Across 12 filings, Tower Research Capital LLC (TRC) increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 463,125 shares valued at US$24.3M — an increase of 87,131 shares quarter over quarter.. Notable position changes include a 2430% increase in Q1 2025 (shares were roughly flat over the following quarter), a 549% increase in Q3 2025 (shares rose 14% over the following quarter), a 1040% increase in Q4 2025 (shares rose 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 717 | $25.99K | New |
| Q4 2023 | 3.79K | $140.61K | Add |
| Q1 2024 | 9.22K | $395.09K | Add |
| Q2 2024 | 29.14K | $1.12M | Add |
| Q3 2024 | 25.05K | $1.02M | Reduce |
| Q4 2024 | 586 | $19.82K | Reduce |
| Q1 2025 | 14.83K | $574.40K | Add |
| Q2 2025 | 3.10K | $119.04K | Reduce |
| Q3 2025 | 20.11K | $867.95K | Add |
| Q4 2025 | 229.21K | $11.24M | Add |
| Q1 2026 | 375.99K | $20.75M | Add |
| Q2 2026 | 463.12K | $24.28M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GSK and 13F data
GSK (GSK PLC) is a Health Care company. 23 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.32B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GSK
- Dodge & Cox 48.20M sh · $2.53B · Q2 2026
- DODGE & COX 48.20M sh · $2.53B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 25.18M sh · $1.32B · Q2 2026
- JTC Employer Solutions Trustee Ltd 8.59M sh · $450.31M · Q2 2026
- Mondrian Investment Partners LTD 4.97M sh · $239.21M · Q3 2026
- Grantham, Mayo, Van Otterloo & Co. LLC 3.60M sh · $188.69M · Q2 2026
- EQUITY INVESTMENT CORP 3.27M sh · $171.40M · Q2 2026
More on Tower Research Capital LLC (TRC)
FAQ
How long has Tower Research Capital LLC (TRC) held GSK?
Tower Research Capital LLC (TRC) has disclosed GSK holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Tower Research Capital LLC (TRC)'s current position in GSK?
As of Q2 2026, Tower Research Capital LLC (TRC) holds 463.12K shares of GSK (GSK PLC), valued at $24.28M, representing 0.59% of its reported portfolio and ranking #29.
Has Tower Research Capital LLC (TRC) been buying or selling GSK?
In the latest 13F filing (Q2 2026), Tower Research Capital LLC (TRC) increased its position in GSK. The position peaked in Q2 2026 at 463.12K shares.
Which other funds hold GSK?
Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 23 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.